This case suggests that, in selected patients with rapidly progressive LMC and limited options, carefully considered palliative osimertinib rechallenge may provide meaningful symptomatic and radiologic benefit despite prior EGFR‐TKI–induced ILD. Here, EGFR is linked to interstitial lung disease.